Clinical Trials
55 trialsNCT04109924 2026-02-10
TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study
Roswell Park Cancer Institute
Phase 2 Completed
NCT00826540 2026-01-20
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT05839951 2025-11-12
STAR-T
Bayer
Completed
NCT05480306 2025-08-03
DeFianCe
Leap Therapeutics, Inc.
Phase 2 Completed
NCT00873275 2025-06-22
Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer
City of Hope Medical Center
Phase 1 Completed
NCT02138617 2025-05-18
Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT03428958 2025-04-23
A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment
NuCana plc
Phase 1/2 Completed
NCT06843954 2025-02-25
Impact of Vascular Endothelial Growth Factor Gene Polymorphisms on Bevacizumab Efficacy in a Sample of Iraqi Patients With Metastatic Colorectal Cancer
Al-Mustansiriyah University
Phase 4 Completed
NCT04164069 2024-12-27
Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT00321828 2024-03-21
Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colon Cancer That Cannot Be Removed By Surgery
NSABP Foundation Inc
Phase 2 Completed
NCT03698461 2024-01-31
CLIMB
Asan Medical Center
Phase 2 Completed
NCT01606098 2023-09-13
CAIRO4
Dutch Colorectal Cancer Group
Phase 3 Completed
NCT00098787 2023-07-05
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00851136 2022-12-13
A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g)
Genentech, Inc.
Phase 1 Completed
NCT00819780 2022-12-06
PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors
Amgen
Phase 2 Completed
NCT00467142 2022-11-01
OMEGA
Institut Bergonié
Phase 2 Completed
NCT00193219 2022-01-11
Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00932438 2021-06-11
DEBIRI
University of Louisville
Phase 1/2 Completed
NCT00423696 2021-02-17
Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
UNICANCER
Phase 2 Completed
NCT00628810 2020-11-09
Combination Chemotherapy and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT01417494 2020-11-03
1st Line Chemotherapy Alone or With Bevacizumab in Treating Older Patients With Metastatic Colorectal Cancer
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT00265850 2020-05-07
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00541125 2020-03-30
G-CSF in Preventing Neutropenia During First-Line Treatment With Chemotherapy and Bevacizumab in Patients With Metastatic Colorectal Cancer
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT00952029 2020-03-30
Combination Chemotherapy and Bevacizumab With or Without Bevacizumab Maintenance Therapy in Treating Patients With Metastatic Colorectal Cancer
Federation Francophone de Cancerologie Digestive
Phase 2/3 Completed
NCT00096278 2019-07-30
Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT01206530 2019-04-18
FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer
Abramson Cancer Center at Penn Medicine
Phase 1/2 Completed
NCT02305758 2018-11-20
Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer
AbbVie
Phase 2 Completed
NCT00418938 2018-10-17
SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial
Amgen
Phase 2 Completed
NCT00911170 2017-12-29
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
Amgen
Phase 3 Completed
NCT00497497 2017-05-19
A Study of PRO95780 in Combination With Cetuximab and Irinotecan Chemotherapy or the FOLFIRI Regimen With Bevacizumab in Patients With Previously Treated Metastatic Colorectal Cancer (APM4187g)
Genentech, Inc.
Phase 1 Completed
NCT01383343 2017-04-19
Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00873756 2016-11-02
A Study of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancer
Genentech, Inc.
Phase 1 Completed
NCT01183663 2016-06-03
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00537901 2015-12-17
First-Line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum - International Study
King Faisal Specialist Hospital & Research Center
Phase NA Completed
NCT00265824 2015-12-11
DREAM
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 3 Completed
NCT00100841 2015-07-27
Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01205022 2015-06-08
Radiolabeled Monoclonal Antibody Therapy, Combination Chemotherapy, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
City of Hope Medical Center
Phase 1 Completed
NCT00077298 2015-04-15
Bevacizumab and Cetuximab With or Without Irinotecan in Treating Patients With Irinotecan-Refractory Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00719797 2015-03-11
TRIBE
Gruppo Oncologico del Nord-Ovest
Phase 3 Completed
NCT00416494 2014-09-03
Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer
Duke University
Phase 2 Completed
NCT00101348 2014-06-11
Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00625651 2014-04-25
Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer
Amgen
Phase 1/2 Completed
NCT00975897 2013-12-19
Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer
National Cancer Institute (NCI)
Phase 2/3 Completed
NCT00062426 2013-11-06
Oxaliplatin and Bevacizumab (Avastinâ„¢) With Either Fluorouracil and Leucovorin or Capecitabine in Treating Patients With Advanced Colorectal Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00060411 2013-09-30
A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00112918 2013-08-27
Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT00006786 2013-06-24
Combination Chemotherapy Plus Bevacizumab in Treating Patients With Advanced Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00066846 2013-06-20
Bevacizumab Plus Fluorouracil and Leucovorin in Treating Patients With Locally Advanced or Metastatic Stage IV Colorectal Cancer That Has Progressed After Standard Chemotherapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT00707889 2013-05-15
Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer
AbbVie
Phase 2 Completed
NCT00290615 2013-05-07
Capecitabine, Cetuximab, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer That Cannot Be Removed By Surgery
Duke University
Phase 2 Completed